NO2007011I1 - Aliskiren eller farmasoytisk akseptable salter derav - Google Patents

Aliskiren eller farmasoytisk akseptable salter derav

Info

Publication number
NO2007011I1
NO2007011I1 NO2007011C NO2007011C NO2007011I1 NO 2007011 I1 NO2007011 I1 NO 2007011I1 NO 2007011 C NO2007011 C NO 2007011C NO 2007011 C NO2007011 C NO 2007011C NO 2007011 I1 NO2007011 I1 NO 2007011I1
Authority
NO
Norway
Prior art keywords
opt
substd
alkylene
cooh
mono
Prior art date
Application number
NO2007011C
Other languages
English (en)
Other versions
NO2007011I2 (no
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4204102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2007011(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO2007011I1 publication Critical patent/NO2007011I1/no
Publication of NO2007011I2 publication Critical patent/NO2007011I2/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
    • C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO2007011C 1994-04-18 2007-10-31 Aliskiren eller farmasoytisk akseptable salter derav NO2007011I1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH116994 1994-04-18

Publications (2)

Publication Number Publication Date
NO2007011I1 true NO2007011I1 (no) 2007-12-11
NO2007011I2 NO2007011I2 (no) 2011-07-25

Family

ID=4204102

Family Applications (4)

Application Number Title Priority Date Filing Date
NO19951441A NO310410B1 (no) 1994-04-18 1995-04-12 Nye <delta>-amino-<gamma>-hydroksy-<omega>-aryl- alkansyreamider, fremgangsmåte for fremstilling herav,farmasöytiske sammensetninger og mellomprodukter, samtforbindelser for anvendelse som terapeutikum
NO2007011C NO2007011I1 (no) 1994-04-18 2007-10-31 Aliskiren eller farmasoytisk akseptable salter derav
NO2009011C NO2009011I2 (no) 1994-04-18 2009-05-18 Kombinasjon omfattende aliskiren, som fri base eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid.
NO2011020C NO2011020I1 (no) 1994-04-18 2011-09-20 Kombinasjon omfattende aliskiren, eller et farmasøytisk akseptabelt salt derav, og amlodipin, eller et farmasøytisk akseptabelt salt derav

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19951441A NO310410B1 (no) 1994-04-18 1995-04-12 Nye <delta>-amino-<gamma>-hydroksy-<omega>-aryl- alkansyreamider, fremgangsmåte for fremstilling herav,farmasöytiske sammensetninger og mellomprodukter, samtforbindelser for anvendelse som terapeutikum

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2009011C NO2009011I2 (no) 1994-04-18 2009-05-18 Kombinasjon omfattende aliskiren, som fri base eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid.
NO2011020C NO2011020I1 (no) 1994-04-18 2011-09-20 Kombinasjon omfattende aliskiren, eller et farmasøytisk akseptabelt salt derav, og amlodipin, eller et farmasøytisk akseptabelt salt derav

Country Status (27)

Country Link
US (5) US5559111A (no)
EP (1) EP0678503B1 (no)
JP (1) JP3240322B2 (no)
KR (1) KR100353779B1 (no)
CN (2) CN1266118C (no)
AT (1) ATE183997T1 (no)
AU (1) AU699616B2 (no)
BR (1) BR1100656A (no)
CA (1) CA2147056C (no)
CY (4) CY2208B1 (no)
CZ (1) CZ287935B6 (no)
DE (4) DE59506707D1 (no)
DK (1) DK0678503T3 (no)
ES (1) ES2137478T3 (no)
FI (1) FI118336B (no)
GR (1) GR3031997T3 (no)
HK (1) HK1070881A1 (no)
HU (2) HU226860B1 (no)
IL (1) IL113403A (no)
LU (2) LU91373I2 (no)
MY (1) MY119161A (no)
NL (2) NL300296I2 (no)
NO (4) NO310410B1 (no)
NZ (1) NZ270936A (no)
RU (1) RU95105970A (no)
TW (2) TW366341B (no)
ZA (3) ZA953050B (no)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4408534A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0716077A1 (de) * 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
ATE260904T1 (de) * 1997-12-16 2004-03-15 Warner Lambert Co ((cyclo)alkyl substituierte)-.gamma.- aminobuttersäure derivate (=gaba analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen
US7354894B2 (en) * 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6833460B2 (en) * 1999-06-18 2004-12-21 E. I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
US6423850B1 (en) 1999-06-18 2002-07-23 E.I. Du Pont De Nemours And Company Preparation and use of gamma-butyrolactones as cross-linking agents
AU5518500A (en) * 1999-07-29 2001-02-19 Speedel Pharma Ag 2-alkyl-5-halogen-pent-4-ene carboxylic acids and their production
EP1296912B1 (en) * 2000-07-03 2006-01-25 Speedel Pharma AG Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
DE60138099D1 (de) * 2000-07-05 2009-05-07 Speedel Pharma Ag Verfahren zur herstellung von substituierten octanoyl-amiden
DE122007000077I2 (de) * 2000-07-25 2008-08-21 Speedel Pharma Ag Hirchgaessle Verfahren zur herstellung von substituierten octanoyl-amiden
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
ES2274847T3 (es) 2000-12-14 2007-06-01 Speedel Pharma Ag Proceso para preparar ariloctanoil-amidas.
JP3440082B2 (ja) 2001-02-19 2003-08-25 科学技術振興事業団 電気自動車用インホイールモーター
IL158586A0 (en) 2001-05-15 2004-05-12 Speedel Pharma Ag Process for the preparation of substituted carboxylic acid esters by enzymatic hydrolysis
WO2002100820A1 (en) * 2001-06-11 2002-12-19 Elan Pharmaceuticals, Inc. Substituted aminoalcohols useful in treatment of alzheimer's disease
EP1448190A2 (en) * 2001-10-18 2004-08-25 Novartis AG Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20050101638A1 (en) * 2002-11-08 2005-05-12 Webb Randy L. Combination of organic compounds
RU2316318C2 (ru) * 2002-05-17 2008-02-10 Новартис Аг Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
AU2003238007A1 (en) * 2002-06-11 2003-12-22 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease using aryl alkanoic acid amides
US20060089355A1 (en) * 2002-06-11 2006-04-27 Michel Maillard Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides
EP1539754A4 (en) * 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
US7049469B2 (en) 2002-10-24 2006-05-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing (R)-salbutamol
BR0316629A (pt) 2002-11-27 2005-10-11 Elan Pharm Inc Uréias e carbamatos substituìdos
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
WO2005019214A1 (en) * 2003-08-25 2005-03-03 Warner-Lambert Company Llc Novel antimicrobial aryloxazolidinone compounds
CN102260188A (zh) * 2003-11-26 2011-11-30 诺瓦提斯公司 有机化合物
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PE20050596A1 (es) * 2003-12-19 2005-10-18 Novartis Ag Microemulsion que comprende un inhibidor renina
BRPI0507030A (pt) * 2004-01-22 2007-06-05 Novartis Ag combinação de compostos orgánicos
PL1735270T3 (pl) * 2004-01-23 2010-12-31 Novartis Ag Dwuaminoalkohole i ich zastosowanie jako inhibitorów reniny
EP1756037B1 (en) * 2004-01-23 2010-12-15 Novartis AG Amino alcohol derivatives and their activity as renin inhibitors
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
EP1729749A2 (en) 2004-03-17 2006-12-13 Novartis AG Use of renin inhibitors in therapy
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
WO2005090304A1 (en) * 2004-03-19 2005-09-29 Speedel Experimenta Ag Organic compounds
EP1712548A3 (en) * 2004-03-19 2006-11-02 Speedel Experimenta AG 5-amino-4-hydroxy-7-(pyridinylmethyl)-alkanamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
WO2005095876A1 (en) 2004-04-01 2005-10-13 Cucumber Limited Delivery and storage of goods
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds
KR20070101843A (ko) 2004-10-08 2007-10-17 노파르티스 아게 확장기 기능장애 또는 확장기 심부전의 예방 또는 치료를위한 레닌 억제제의 용도
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
TW200633983A (en) * 2004-12-10 2006-10-01 Speedel Experimenta Ag 5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
JP2008528691A (ja) * 2005-02-02 2008-07-31 ビテ ファーマシューティカルズ， インコーポレイテッド レニン阻害剤としての１−アシルアミノ−２−ヒドロキシ−３−アミノ−ω−アリールアルカン
TW200700358A (en) * 2005-03-11 2007-01-01 Speedel Experimenta Ag Organic compounds
CN101171230A (zh) * 2005-03-11 2008-04-30 斯皮德尔实验股份公司 用作肾素抑制剂的杂环取代的链烷酰胺
ES2337826T3 (es) * 2005-03-17 2010-04-29 Basf Se Metodo para la produccion de derivados opticamente activos de acido 3-fenilpropionico y productos de reaccion del mismo.
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
JP5123178B2 (ja) * 2005-07-11 2013-01-16 ノバルティス アーゲー 新規ピロカテキン誘導体
US20070021413A1 (en) 2005-07-20 2007-01-25 Peter Herold Diamino alcohols as therapeutic compounds
US8063105B2 (en) 2005-07-22 2011-11-22 Merck Canada Inc. Renin inhibitors
EP1764098A1 (en) * 2005-09-17 2007-03-21 Speedel Experimenta AG Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
PL1937248T3 (pl) * 2005-09-17 2010-11-30 Novartis Ag Amidy kwasów alkanowych podstawione nasyconymi grupami O-heterocyklicznymi
JP2009507900A (ja) 2005-09-17 2009-02-26 シュペーデル・エクスペリメンタ・アーゲー 高血圧の処置のためのレニン阻害剤としての５−アミノ−４−ヒドロキシ−７−（イミダゾ［１，２−ａ］ピリジン−６−イルメチル）−８−メチル−ノナミド誘導体および関連化合物
GB0519764D0 (en) * 2005-09-28 2005-11-09 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
JP2009514809A (ja) * 2005-10-18 2009-04-09 ニコックス エス エイ レニン阻害剤のニトロ誘導体
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
GB2431648A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431645A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431646A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
GB2431642A (en) * 2005-10-25 2007-05-02 Novartis Ag Alternative synthesis of aryl-octanoyl amide compounds
DE102005052195A1 (de) * 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
WO2007123718A1 (en) * 2006-03-31 2007-11-01 Vitae Pharmaceuticals, Inc. 1-HETEROCYCLYLAMINO-2-HYDROXY-3-AMINO-ω-ARYLALKANES
WO2007120523A2 (en) * 2006-03-31 2007-10-25 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
MX2008012729A (es) * 2006-04-03 2008-10-14 Novartis Ag Inhibidores de renina para el tratamiento de hipertension.
EP2036896B1 (en) 2006-06-23 2012-03-14 Daiichi Sankyo Company, Limited Cyclic amine compound
TW200815324A (en) * 2006-06-23 2008-04-01 Daiichi Sankyo Co Ltd Straight chain amine compound
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
AU2007276433B2 (en) 2006-07-20 2011-06-16 Novartis Ag Amino-piperidine derivatives as CETP inhibitors
EP1911762A1 (en) 2006-10-04 2008-04-16 Speedel Experimenta AG Amino alcohols and their use as renin inhibitors
PE20121179A1 (es) * 2006-11-07 2012-09-13 Novartis Ag Forma cristalina de hemifumarato de alisquireno
CN101528672A (zh) * 2006-11-09 2009-09-09 诺瓦提斯公司 阿利吉仑乳清酸盐
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
EP1958666A1 (en) 2007-02-13 2008-08-20 Speedel Experimenta AG Heterocyclic-substituted alkanamides as therapeutic compounds
AR065792A1 (es) * 2007-03-21 2009-07-01 Speedel Experimenta Ag Proceso para preparar (r o s) -5- (1 -azido-3-(6-metoxi-5-(3-metoxi-propoxi) -piridin-3-ilmetil) -4-metil- pentil) -3-alquil-dihidro-furan-2-ona
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
MX2009010699A (es) * 2007-04-03 2010-03-10 Novartis Ag Nuevos metodos.
EP2173696A1 (en) 2007-07-11 2010-04-14 DSM IP Assets B.V. Preparation of a saturated aldehyde
US20090076062A1 (en) * 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
JP5378384B2 (ja) 2007-09-28 2013-12-25 ノバルティス アーゲー 有機化合物のガレヌス製剤
DE102007049039A1 (de) 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
WO2009059943A1 (en) 2007-11-05 2009-05-14 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
JP2011503185A (ja) 2007-11-13 2011-01-27 テバ ファーマシューティカル インダストリーズ リミティド ヘミフマル酸アリスキレンの多形形態及びその調製プロセス
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
CA2707651A1 (en) 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
EP2075244A1 (en) 2007-12-24 2009-07-01 DSMIP Assets B.V. New route to building block for making renin inhibitors
EP2255796A2 (en) 2008-02-22 2010-12-01 HanAll Biopharma Co., Ltd. Pharmaceutical preparation
CN101990428A (zh) 2008-04-10 2011-03-23 韩兀生物制药株式会社 药物制剂
US20100029774A1 (en) * 2008-05-23 2010-02-04 Nina Finkelstein Aliskiren monofumarate and processes for preparation thereof
CA2724320A1 (en) * 2008-06-06 2009-12-10 Teva Pharmaceutical Industries Ltd. Solid states of aliskiren free base
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
EP2163245A1 (en) 2008-09-10 2010-03-17 Novartis Ag Renin inhibitors for the treatment of psoriasis
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
EP2391345B1 (en) 2009-01-28 2014-09-03 Novartis AG Galenic formulations comprising aliskiren
EA201190091A1 (ru) 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
US8148576B2 (en) * 2009-02-05 2012-04-03 Teva Pharmaceutical Industries Ltd. Solid state forms of aliskiren compounds
JP2012520895A (ja) 2009-03-20 2012-09-10 ノバルティス アーゲー バルサルタンおよびアリスキレンの一定用量の組合せのガレヌス製剤
US20120003308A1 (en) 2009-03-20 2012-01-05 Sonali Bose Pharmaceutical Composition Comprising Aliskiren
WO2010112482A1 (en) 2009-04-01 2010-10-07 Lek Pharmaceuticals D.D. A process for dimethylation of active methylene groups
US8779198B2 (en) 2009-08-11 2014-07-15 Novartis Ag Ring opening of lactones and lactams
US20120220663A1 (en) 2009-09-03 2012-08-30 Teva Pharmaceuticals Usa, Inc. Solid forms of aliskiren hemifumarate and processes for preparation thereof
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011048523A1 (en) * 2009-10-21 2011-04-28 CarboDesign LLC Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
US20130005730A1 (en) * 2009-11-09 2013-01-03 Piaoyang Sun Novel 1,3-oxazolidine compounds and their use as renin inhibitors
US20110113995A1 (en) * 2009-11-13 2011-05-19 Lindsay Corporation Method and apparatus for planting and irrigation
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CN101774986B (zh) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102140068B (zh) * 2010-01-30 2015-03-11 浙江华海药业股份有限公司 阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
EP2523934A1 (en) * 2010-02-10 2012-11-21 Ratiopharm GmbH Salts of aliskiren
WO2011116115A1 (en) 2010-03-16 2011-09-22 Novartis Ag Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
TR201002256A1 (tr) * 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
US20110268797A1 (en) 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
TW201202178A (en) 2010-06-04 2012-01-16 Chemo Iberica Sa Process for producing Aliskiren
IT1400961B1 (it) * 2010-06-04 2013-07-05 Chemo Iberica Sa Processo per la produzione di aliskiren
IT1402925B1 (it) * 2010-12-10 2013-09-27 Chemo Iberica Sa Processo per la produzione di aliskiren
CN101913998A (zh) * 2010-07-06 2010-12-15 上海朴颐化学科技有限公司 4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法
WO2012034065A1 (en) 2010-09-09 2012-03-15 Teva Pharmaceutical Industries Ltd. Aliskiren intermediates and a process for analyzing the purity of aliskiren
EP2630118B1 (en) 2010-10-19 2014-11-05 Mylan Laboratories Limited Synthesis of aliskiren
CN102001920B (zh) 2010-11-09 2013-05-15 常州制药厂有限公司 一种药物中间体的制备方法
CN102161627A (zh) * 2011-02-24 2011-08-24 中国药科大学 ω-(N取代-氨基烷基)辛酰胺
EP2551260A1 (en) 2011-07-28 2013-01-30 Chemo Ibérica, S.A. Chemical process for opening ring compounds
CN102942477B (zh) * 2011-08-14 2015-12-02 浙江华海药业股份有限公司 辛烯酸衍生物及其制备方法
CN102351734B (zh) * 2011-09-05 2014-02-26 浙江普洛医药科技有限公司 一种阿利克仑的制备方法
WO2013045505A1 (en) 2011-09-28 2013-04-04 Novartis Ag Biomarkers for raas combination therapy
US8703976B2 (en) * 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
US9056816B2 (en) 2011-10-25 2015-06-16 Jubilant Life Sciences Limited Process for the preparation of aliskiren
WO2013118138A1 (en) 2011-12-13 2013-08-15 Laboratories Ltd Mylan Novel process for the preparation of renin inhibitors
CN103172533B (zh) * 2011-12-20 2016-05-04 博瑞生物医药（苏州）股份有限公司 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
CN103204834A (zh) * 2012-01-11 2013-07-17 南京欧信医药技术有限公司 阿利克伦中间体及其制备方法和应用
US9090537B2 (en) 2012-02-17 2015-07-28 Mylan Laboratories Limited Process for the preparation of aliskiren
WO2013124868A2 (en) 2012-02-21 2013-08-29 Mylan Laboratories Limited Solid form of aliskiren intermediate
ITMI20120354A1 (it) * 2012-03-07 2013-09-08 Friulchem Spa Processo per la produzione di aliskirene
WO2013144979A1 (en) 2012-03-28 2013-10-03 Maylan Laboratories Ltd Process for the preparation of aliskiren
KR102063542B1 (ko) 2012-05-11 2020-01-09 필립스-메디사이즈 에이/에스 분배 장치
WO2013171767A1 (en) 2012-05-18 2013-11-21 Mylan Laboratories Limited An improved process for the preparation of aliskiren
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
WO2014207206A1 (en) * 2013-06-27 2014-12-31 Dpx Holdings B.V. Preparation of grignard reagents using a fluidized bed
CN117542473A (zh) 2018-06-14 2024-02-09 阿斯利康(英国)有限公司 用血管紧张素ii受体阻滞剂医药组合物治疗高血压的方法
CN112679448B (zh) * 2020-12-31 2022-08-19 苏州昊帆生物股份有限公司 N-(2-氨基乙基)吗啉的制备方法
CN115340472B (zh) * 2022-09-19 2024-05-07 合肥工业大学 一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337207A (en) * 1980-09-04 1982-06-29 Regents Of The University Of California Biologically active catecholamine derivatives
US4729985A (en) * 1985-08-09 1988-03-08 Pfizer Inc. Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
JPH02124884A (ja) * 1988-07-08 1990-05-14 Zhongguo Yixuekexueyuan Yaowo Yanjiusuo Ｎ―置換アミド誘導体
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities

Also Published As

Publication number Publication date
EP0678503B1 (de) 1999-09-01
DE122007000071I2 (de) 2009-01-02
CY2208B1 (en) 2002-11-08
CN1266118C (zh) 2006-07-26
LU91564I2 (fr) 2009-07-06
GR3031997T3 (en) 2000-03-31
CY2009006I1 (el) 2010-07-28
CY2011015I2 (el) 2014-04-09
ZA953051B (en) 1995-10-18
NO2009011I1 (no) 2009-06-02
BR1100656A (pt) 2000-06-06
NL300296I1 (nl) 2007-12-03
JPH0881430A (ja) 1996-03-26
FI951771A (fi) 1995-10-19
ZA953050B (en) 1995-11-08
NO2009011I2 (no) 2010-11-22
ATE183997T1 (de) 1999-09-15
NL300296I2 (nl) 2008-02-01
NO310410B1 (no) 2001-07-02
US5559111A (en) 1996-09-24
US5654445A (en) 1997-08-05
IL113403A0 (en) 1995-07-31
NO2011020I1 (no) 2011-09-26
US5705658A (en) 1998-01-06
US5646143A (en) 1997-07-08
HU226860B1 (en) 2009-12-28
DE59506707D1 (de) 1999-10-07
NZ270936A (en) 1997-06-24
CN1550491A (zh) 2004-12-01
HU9501076D0 (en) 1995-06-28
CY2007027I1 (el) 2009-11-04
KR100353779B1 (ko) 2003-01-08
TW366341B (en) 1999-08-11
AU1642195A (en) 1995-10-26
CA2147056C (en) 2005-10-25
HU9501078D0 (en) 1995-06-28
CY2009006I2 (el) 2010-07-28
JP3240322B2 (ja) 2001-12-17
NO951441D0 (no) 1995-04-12
DE122007000071I1 (de) 2008-01-31
CY2011015I1 (el) 2014-04-09
EP0678503A1 (de) 1995-10-25
NL300386I1 (nl) 2009-07-01
CY2007027I2 (el) 2009-11-04
FI118336B (fi) 2007-10-15
CN1153759C (zh) 2004-06-16
MY119161A (en) 2005-04-30
NO2007011I2 (no) 2011-07-25
NO951441L (no) 1995-10-19
HUT71701A (en) 1996-01-29
RU95105970A (ru) 1997-01-10
DK0678503T3 (da) 2000-03-20
LU91373I2 (fr) 2007-12-31
DE122009000020I1 (de) 2009-08-06
CN1117960A (zh) 1996-03-06
CA2147056A1 (en) 1995-10-19
KR950032037A (ko) 1995-12-20
US5627182A (en) 1997-05-06
FI951771A0 (fi) 1995-04-12
CZ287935B6 (cs) 2001-03-14
AU699616B2 (en) 1998-12-10
CZ97695A3 (en) 1995-11-15
ES2137478T3 (es) 1999-12-16
TW402582B (en) 2000-08-21
HUT74074A (en) 1996-10-28
DE122011100052I1 (de) 2012-01-19
IL113403A (en) 2001-07-24
HK1070881A1 (en) 2005-06-30
ZA953052B (en) 1995-10-18

Similar Documents

Publication Publication Date Title
NO2007011I1 (no) Aliskiren eller farmasoytisk akseptable salter derav
AR017111A1 (es) Composiciones detergentes para el lavado de ropa con polimeros a base de aminas lineales para proporcionar beneficios en cuanto a aspecto exterior eintegridad a las telas lavadas con las mismas
KR960017644A (ko) 신규한 설폰아미드
ES2104987T3 (es) Derivados de eteres milbemicina, su preparacion y su aplicacion terapeutica y agroquimica.
FI973894A0 (fi) 9-substituoidut porfyseenit
BR9505989A (pt) Processo para preparação de aldeídos
DK0953563T3 (da) Fremgangsmåde til fremstilling af depsipeptidderivater samt hidtil ukendte intermediater derfor
ES2062062T3 (es) Procedimiento para la preparacion de eteres de la 2-amino-7-hidroxitetralina.
SU1793713A1 (ru) Сополиамид, содержащий группы сульфоната пиперазина

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NODEN PHARMACEUTICALS DAC, IE